Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Circulating microRNAs in breast cancer : novel diagnostic and prognostic biomarkers. / Hamam, Rimi; Hamam, Dana; Alsaleh, Khalid A.; Kassem, Moustapha; Zaher, Waleed; Alfayez, Musaad; Aldahmash, Abdullah; Alajez, Nehad M.
I: Cell Death & Disease, Bind 8, Nr. 9, e3045, 2017.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Circulating microRNAs in breast cancer
T2 - novel diagnostic and prognostic biomarkers
AU - Hamam, Rimi
AU - Hamam, Dana
AU - Alsaleh, Khalid A.
AU - Kassem, Moustapha
AU - Zaher, Waleed
AU - Alfayez, Musaad
AU - Aldahmash, Abdullah
AU - Alajez, Nehad M.
PY - 2017
Y1 - 2017
N2 - Effective management of breast cancer depends on early diagnosis and proper monitoring of patients' response to therapy. However, these goals are difficult to achieve because of the lack of sensitive and specific biomarkers for early detection and for disease monitoring. Accumulating evidence in the past several years has highlighted the potential use of peripheral blood circulating nucleic acids such as DNA, mRNA and micro (mi)RNA in breast cancer diagnosis, prognosis and for monitoring response to anticancer therapy. Among these, circulating miRNA is increasingly recognized as a promising biomarker, given the ease with which miRNAs can be isolated and their structural stability under different conditions of sample processing and isolation. In this review, we provide current state-of-the-art of miRNA biogenesis, function and discuss the advantages, limitations, as well as pitfalls of using circulating miRNAs as diagnostic, prognostic or predictive biomarkers in breast cancer management.
AB - Effective management of breast cancer depends on early diagnosis and proper monitoring of patients' response to therapy. However, these goals are difficult to achieve because of the lack of sensitive and specific biomarkers for early detection and for disease monitoring. Accumulating evidence in the past several years has highlighted the potential use of peripheral blood circulating nucleic acids such as DNA, mRNA and micro (mi)RNA in breast cancer diagnosis, prognosis and for monitoring response to anticancer therapy. Among these, circulating miRNA is increasingly recognized as a promising biomarker, given the ease with which miRNAs can be isolated and their structural stability under different conditions of sample processing and isolation. In this review, we provide current state-of-the-art of miRNA biogenesis, function and discuss the advantages, limitations, as well as pitfalls of using circulating miRNAs as diagnostic, prognostic or predictive biomarkers in breast cancer management.
U2 - 10.1038/cddis.2017.440
DO - 10.1038/cddis.2017.440
M3 - Journal article
C2 - 28880270
VL - 8
JO - Cell Death & Disease
JF - Cell Death & Disease
SN - 2041-4889
IS - 9
M1 - e3045
ER -
ID: 183835705